心脏冲击波治疗联合冠脉搭桥改善缺血性心衰患者心肌功能:CAST-HF试验
CAST-HF为单盲、平行组、假对照试验,纳入63例LVEF≤40%需外科血运重建的缺血性心衰患者,随机接受直接心脏冲击波治疗(SWT)或假治疗联合冠脉搭桥。
要点
- 心脏冲击波治疗联合冠脉搭桥可进一步改善缺血性心衰患者LVEF。
- SWT组6分钟步行距离改善优于假组,生活质量评分组间无显著差异。
- 两组各报告2例非器械相关死亡(治疗组)。
核心结论
- 直接心脏冲击波治疗联合冠脉搭桥可改善缺血性心衰患者的LVEF和体力活动能力。
研究设计与样本
- 单盲、平行组、假对照试验(CAST-HF;NCT03859466),纳入LVEF≤40%需外科血运重建的缺血性心衰患者63例,随机接受直接心脏SWT或假治疗联合冠脉搭桥。
主要发现
- SWT组30例和假组28例完成主要终点1年随访。
- 治疗组2例患者因非器械相关原因死亡。
临床怎么用
- 对于需冠脉搭桥的缺血性心衰(LVEF≤40%)患者,可考虑在搭桥基础上加用直接心脏冲击波治疗以改善LVEF和运动耐量。
局限性
- 单盲设计,假对照设置。
- 生活质量评分组间差异未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In chronic ischaemic heart failure, revascularisation strategies control symptoms but are less effective in improving left ventricular ejection fraction (LVEF). The aim of this trial is to investigate the safety of cardiac shockwave therapy (SWT) as a novel treatment option and its efficacy in increasing cardiac function by inducing angiogenesis and regeneration in hibernating myocardium. METHODS: In this single-blind, parallel-group, sham-controlled trial (cardiac shockwave therapy for ischemic heart failure, CAST-HF; NCT03859466) patients with LVEF ≤40% requiring surgical revascularisation were enrolled. Patients were randomly assigned to undergo direct cardiac SWT or sham treatment in addition to coronary bypass surgery. The primary efficacy endpoint was the improvement in LVEF measured by cardiac magnetic resonance imaging from baseline to 360 days. RESULTS: Overall, 63 patients were randomized, out of which 30 patients of the SWT group and 28 patients of the Sham group attained 1-year follow-up of the primary endpoint. Greater improvement in LVEF was observed in the SWT group (Δ from baseline to 360 days: SWT 11.3%, SD 8.8; Sham 6.3%, SD 7.4, P = .0146). Secondary endpoints included the 6-minute walking test, where patients randomized in the SWT group showed a greater Δ from baseline to 360 days (127.5 m, SD 110.6) than patients in the Sham group (43.6 m, SD 172.1) (P = .028) and Minnesota Living with Heart Failure Questionnaire score on day 360, which was 11.0 points (SD 19.1) for the SWT group and 17.3 points (SD 15.1) for the Sham group (P = .15). Two patients in the treatment group died for non-device-related reasons. CONCLUSIONS: In conclusion, the CAST-HF trial indicates that direct cardiac SWT, in addition to coronary bypass surgery improves LVEF and physical capacity in patients with ischaemic heart failure.
引用
- Holfeld, Nägele, Pölzl, et al. Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial. Eur Heart J. 2024. PMID: 38898573. doi:10.1093/eurheartj/ehae341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。